HS-1793 inhibits cell proliferation in lung cancer by interfering with the interaction between p53 and MDM2

被引:6
作者
Lim, Chungun [1 ,2 ]
Lee, Peter C. W. [1 ,2 ,3 ]
Shim, Sungbo [4 ,5 ]
Jang, Sung-Wuk [1 ,2 ,3 ,6 ]
机构
[1] Univ Ulsan, Asan Med Ctr, Dept Biomed Sci, Coll Med, Seoul 138736, South Korea
[2] Univ Ulsan, Asan Med Inst Convergence Sci & Technol, Asan Med Ctr, Coll Med, Seoul 138736, South Korea
[3] Univ Ulsan, Dept Biochem & Mol Biol, Coll Med, Seoul 138736, South Korea
[4] Chungbuk Natl Univ, Coll Nat Sci, Dept Biochem, Cheongju 28644, South Korea
[5] Chungbuk Natl Univ, Coll Nat Sci, Dept Biochem, 1 Chungdae Ro, Cheongju 28644, South Korea
[6] Univ Ulsan, Asan Med Ctr, Dept Biomed Sci, Coll Med, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea
基金
新加坡国家研究基金会;
关键词
HS-1793; p53; MDM2; anti-cancer; lung cancer; RESVERATROL ANALOG; PROSTATE-CANCER; BREAST-CANCER; DOWN-REGULATION; CYCLE ARREST; DEATH; ACTIVATION; BIOLOGY; AKT;
D O I
10.3892/ol.2022.13410
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The transcription factor or tumor suppressor protein p53 regulates numerous cellular functions, including cell proliferation, invasion, migration, senescence and apoptosis, in various types of cancer. HS-1793 is an analog of resveratrol, which exhibits anti-cancer effects on various types of cancer, including breast, prostate, colon and renal cancer, and multiple myeloma. However, to the best of our knowledge, the role of HS-1793 in lung cancer remains to be examined. The present study aimed to investigate the anti-cancer effect of HS-1793 on lung cancer and to determine its association with p53. The results revealed that HS-1793 reduced cell proliferation in lung cancer and increased p53 stability, thereby elevating the expression levels of the target genes p21 and mouse double minute 2 homolog (MDM2). When the levels of MDM2, a negative regulator of p53, are increased under normal conditions, MDM2 binds and degrades p53; however, HS-1793 inhibited this binding, confirming that p53 protein stability was increased. In conclusion, the findings of the present study provide new evidence that HS-1793 may inhibit lung cancer proliferation by disrupting the p53-MDM2 interaction.
引用
收藏
页数:9
相关论文
共 51 条
[1]   Resveratrol as MDR reversion molecule in breast cancer: An overview [J].
Alamolhodaei, Nafiseh Sadat ;
Tsatsakis, Aristidis M. ;
Ramezani, Mohammad ;
Hayes, A. Wallace ;
Karimi, Gholamreza .
FOOD AND CHEMICAL TOXICOLOGY, 2017, 103 :223-232
[2]   Pharmacological Activation of p53 in Cancer Cells [J].
Athar, Mohammad ;
Elmets, Craig A. ;
Kopelovich, Levy .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (06) :631-639
[3]   How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? [J].
Aubrey, Brandon J. ;
Kelly, Gemma L. ;
Janic, Ana ;
Herold, Marco J. ;
Strasser, Andreas .
CELL DEATH AND DIFFERENTIATION, 2018, 25 (01) :104-113
[4]   Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway [J].
Chen, Yueming ;
Li, Huachao ;
Zhang, Weinan ;
Qi, Wanchen ;
Lu, Changpeng ;
Huang, Huiliang ;
Yang, Zhicheng ;
Liu, Bing ;
Zhang, Luyong .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 387
[5]   Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy [J].
Chène, P .
NATURE REVIEWS CANCER, 2003, 3 (02) :102-109
[6]   Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis [J].
Chibaya, Loretah ;
Karim, Baktiar ;
Zhang, Hong ;
Jones, Stephen N. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (04)
[7]   Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses [J].
Ebi, Hiromichi ;
Tomida, Shuta ;
Takeuchi, Toshiyuki ;
Arima, Chinatsu ;
Sato, Takahiko ;
Mitsudomi, Tetsuya ;
Yatabe, Yasushi ;
Osada, Hirotaka ;
Takahashi, Takashi .
CANCER RESEARCH, 2009, 69 (09) :4027-4035
[8]   Resveratrol regulates p66Shc activation in HaCaT cells [J].
Fabbrocini, Gabriella ;
Kisslinger, Annamaria ;
Iannelli, Paola ;
Vitale, Nicoletta ;
Procaccini, Claudio ;
Sparaneo, Giuseppina ;
Chieffi, Paolo ;
Ayala, Fabio ;
Mancini, Francesco Paolo ;
Tramontano, Donatella .
EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) :895-903
[9]  
Feng Y, 2016, J BUON, V21, P950
[10]  
Gridelli C, 2015, NAT REV DIS PRIMERS, V1, DOI [10.1038/nrdp.2015.48, 10.1038/nrdp.2015.9, 10.1038/nrdp.2015.48]